OpportunityAnalyzer: Sepsis and Septic Shock - Opportunity Analysis and Forecasts to 2026

Tuesday, November 7, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

OpportunityAnalyzer: Sepsis and Septic Shock - Opportunity Analysis and Forecasts to 2026

LONDON, Nov. 7, 2017 /PRNewswire/ --

Download the full report: https://www.reportbuyer.com/product/5175850SummarySepsis

is a complex disease, which not only involves a wide array of causative agents, but also results in different individual immune responses causing various single or multiple organ dysfunction(s). In late 2016, the sepsis and septic shock market abandoned the concept of a systemic immune response syndrome in the presence of an infection as a potential cause for sepsis; in the new consensus definitions, sepsis is defined as an infection leading to organ dysfunction.It is estimated that in 2015, the overall sales for sepsis and septic shock to be approximately US$2.8 Billion, comprising annual drug sales of US$2.2 Billion in sepsis and US$0.6 Billion in septic shock across the 7MM. Differences in revenue generated by disease area are due to higher incidence rates for sepsis compared with septic shock. GlobalData expects the sepsis and septic shock market to grow by a strong Compound Annual Growth Rate (CAGR) of 7.9% from 2016-2026, reaching annual sales of US$5.9 Billion by the end of the forecast period.In order to combat these market realities, we believe developers will have to leverage innovative R&D strategies to establish the strong clinical evidence needed for approval and uptake post-licensure. Some of the key approaches identified by KOLs include adaptive clinical trial design, including interim analyses leveraging multiple clinically relevant biomarkers and companion diagnostics to limit heterogeneity among enrolled patients; targeting highly specific sepsis patient populations based on sepsis-induced conditions; and investigating novel targets with combination therapies that are relevant to sepsis pathophysiology.The report "OpportunityAnalyzer: Sepsis and Septic Shock - Opportunity Analysis and Forecasts to 2026", covers overview of sepsis and septic shock, including epidemiology, etiology, pathophysiology, as well as current routine sepsis and septic shock recommendations of all 7MM covered.This report provides the following in-depth analysis -- Top-line sepsis and septic shock market revenue from 2016-2026. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and influence of new consensus definitions for the sepsis and septic shock market.- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.- Analysis of the current and future market competition in the global sepsis and septic shock marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Companies mentioned in this report: AM-Pharma, Asahi Kasei Pharma Corp, Bristol-Myers Squibb, CytoSorbents, Faron, Ferring Holding, Pfizer, RevImmune, Shionogi, Spectral Diagnostics.Scope- Overview of sepsis and septic shock, including epidemiology, etiology, pathophysiology, as well current routine sepsis and septic shock recommendations of all 7MM covered.- Top-line sepsis and septic shock market revenue from 2016-2026. Recent acquisitions, approvals and governmental recommendations are included in the forecast model.- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, clinical trial design, and influence of new consensus definitions for the sepsis and septic shock market.- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.- Analysis of the current and future market competition in the global sepsis and septic shock marketplace. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.Reasons to buyThe report will enable you to -- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.- Develop business strategies by understanding the trends shaping and driving the global sepsis and septic shock market.- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the sepsis and septic shock market in the future.- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.Download the full report: https://www.reportbuyer.com/product/5175850 About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers https://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: [email protected] Tel: +44 208 816 85 48 Website: www.reportbuyer.com

View original content:http://www.prnewswire.com/news-releases/opportunityanalyzer-sepsis-and-septic-shock---opportunity-analysis-and-forecasts-to-2026-300550721.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store